<DOC>
	<DOCNO>NCT00035256</DOCNO>
	<brief_summary>The purpose study determine whether increase spine bone mineral density generally observe previous clinical study involve study drug maintain even increase follow raloxifene HCl . All qualify study participant receive study drug follow treatment raloxifene HCl placebo . All study participant receive raloxifene HCl third phase study .</brief_summary>
	<brief_title>Sequential Use Teriparatide Raloxifene HCl Treatment Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Must diagnose osteoporosis Must female , age 55 80 Must least 5 year postmenopausal Must free severe chronically disable condition Must able properly use injection device . Must bone diseases osteoporosis Must history certain cancer Must certain medical disease ( inflammatory bowel disease , malabsorption syndrome , kidney bladder stone , venous thrombus embolus , recent vaginal bleeding due unknown cause ) Must treatment particular medication ( warfarin , estrogens , androgen , steroid , calcitonin , fluoride , biphosphonates ) Must know allergy study agent raloxifene HCl</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>